

Notice of Allowability	Application No.	Applicant(s)
	09/775,803	RAMAKRISHNAN ET AL.
	Examiner Brian Whiteman	Art Unit 1635

- The MAILING DATE of this communication appears on the cover sheet with the correspondence address-

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTO-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to the amendment filed on 10/14/04.
2. The allowed claim(s) is/are 1,3,5,10,15,21,23,26 and 28-30.
3. The drawings filed on 31 March 2003 are accepted by the Examiner.
4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All
 - b) Some*
 - c) None
 of the:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No./Mail Date _____.
 - (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. Notice of References Cited (PTO-892)
2. Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date _____
4. Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. Notice of Informal Patent Application (PTO-152)
6. Interview Summary (PTO-413),
Paper No./Mail Date _____.
7. Examiner's Amendment/Comment
8. Examiner's Statement of Reasons for Allowance
9. Other _____.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Tracy Sioussat on 12/16/04.

The application has been amended as follows:

Claims 24 and 27 are cancelled because the claims do not further limit the claims from which they depend.

The term "mouse" on line 2 in Claim 1 has been replaced with the term -- mouse's genome --.

The term -- gene -- has been inserted after the term "GP V" on line 3 of Claim 1.

The term "mouse" on line 2 in Claim 5 has been replaced with the term -- mouse's genome --.

The term -- gene -- has been inserted after the term “GP V” on line 3 of Claim 5.

The term -- gene -- has been inserted after the term “GP V” on line 7 of Claim 5.

The term “homozygous” on line 12 in Claim 5 has been replaced with the term -- homozygotic --.

The term “mouse” on line 2 in Claim 10 has been replaced with the term -- mouse’s genome --.

The term -- gene -- has been inserted after the term “GP V” on line 4 of Claim 10.

The term -- gene -- has been inserted after the term “GP V” on line 7 of Claim 10.

The term “disrupted or” on line 13, Claim 10 has been deleted from the claim.

The term “mouse” on line 2 in Claim 15 has been replaced with the term -- mouse’s genome --.

The term -- gene -- has been inserted after the term “GP V” on line 4 of Claim 15.

The term “mouse” on line 3 in Claim 21 has been replaced with the term -- mouse’s genome --.

The term -- gene -- has been inserted after the term “GP V” on line 4 of Claim 21.

The term “mouse” on line 3 in Claim 23 has been replaced with the term -- mouse’s genome --.

The term -- gene -- has been inserted after the term “GP V” on line 4 of Claim 23.

The term “mouse” on line 3 in Claim 28 has been replaced with the term -- mouse’s genome --.

The term -- gene -- has been inserted after the term “GP V” on line 4 of Claim 28.

The term “mouse” on line 3 in Claim 29 has been replaced with the term -- mouse’s genome --.

The term -- gene -- has been inserted after the term “GP V” on line 4 of Claim 29.

The term "mouse" on line 3 in Claim 30 has been replaced with the term -- mouse's genome --.

The term -- gene -- has been inserted after the term "GP V" on line 4 of Claim 30.

Examiner's Comments

Oath/Declaration

The oath or declaration is defective. A new oath or declaration in compliance with 37 CFR 1.67(a) identifying this application by application number and filing date is required. See first inventor's address. See MPEP §§ 602.01 and 602.02.

The oath or declaration is defective because:

Non-initialed and/or non-dated alterations have been made to the oath or declaration. See 37 CFR 1.52(c).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Whiteman whose telephone number is (571) 272-0764. The examiner can normally be reached on Monday through Friday from 7:00 to 4:00 (Eastern Standard Time), with alternating Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader, SPE - Art Unit 1635, can be reached at (571) 272-0760.

Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center number is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Brian Whiteman
Patent Examiner, Group 1635

Scott D. Priebe
SCOTT D. PRIEBE, PH.D
PRIMARY EXAMINER